Tumor Necrosis Factor-α Induces Endothelial Dysfunction in Lepr ^db Mice

Abstract

Background-We hypothesized that the inflammatory cytokine tumor necrosis factor-␣ (TNF) produces endothelial dysfunction in type 2 diabetes. Methods and Results-In m Leprdb control mice, sodium nitroprusside and acetylcholine induced dose-dependent vasodilation, and dilation to acetylcholine was blocked by the NO synthase inhibitor N G -monomethyl-L-arginine. In type 2 diabetic (Lepr db ) mice, acetylcholine-or flow-induced dilation was blunted compared with m Lepr db , but sodium nitroprusside produced comparable dilation. In Lepr db mice null for TNF (db TNFϪ /db TNFϪ ), dilation to acetylcholine or flow was greater than in diabetic Lepr db mice and comparable to that in controls. Plasma concentration of TNF was significantly increased in Lepr db versus m Lepr db mice. Real-time polymerase chain reaction and Western blotting showed that mRNA and protein expression of TNF and nuclear factor-B were higher in Lepr db mice than in controls. Administration of anti-TNF or soluble receptor of advanced glycation end products attenuated nuclear factor-B and TNF expression in the Lepr db mice. Immunostaining results show that TNF in mouse heart is localized predominantly in vascular smooth muscle cells rather than in endothelial cells and macrophages. Superoxide generation was elevated in vessels from Lepr db mice versus controls. Administration of the superoxide scavenger TEMPOL, NAD(P)H oxidase inhibitor (apocynin), or anti-TNF restored endothelium-dependent dilation in Lepr db mice. NAD(P)H oxidase activity, protein expression of nitrotyrosine, and hydrogen peroxide production were increased in Lepr db mice (compared with controls), but these variables were restored to control levels by anti-TNF. Conclusion-Advanced glycation end products/receptor of advanced glycation end products and nuclear factor-B signaling play pivotal roles in TNF expression through an increase in circulating and/or local vascular TNF production in the Lepr db mouse with type 2 diabetes. Increases in TNF expression induce activation of NAD(P)H oxidase and production of reactive oxidative species, leading to endothelial dysfunction in type 2 diabetes. (Circulation. 2007;115: 245-254.)

Mechanism of the protective effects of the combined treatment with rhynchophylla total alkaloids and sinapine thiocyanate against a prothrombotic state caused by vascular endothelial cell inflammatory damage

“…After binding to the TNF-α receptor on the cell membrane of VECs, TNF-α exerts its biological effect via multiple pathways (11)(12)(13)(14)(15) to induce inflammation and alter coagulant/fibrinolytic function of VECs (16), leading to inflammation and coagulation. In the present study, a TNF-α-induced VEC injury model was established to investigate alterations in cell morphology and subcellular structures.…”

Cardiac remodeling and diastolic dysfunction in DahlS.Z-Leprfa/Leprfa rats: a new animal model of metabolic syndrome

“…36 Increases in TNF-a expression induce activation of NADPH oxidase and production of ROS. 37 Increased myocardial IL-6 expression is associated with the progression of heart failure. 38 IL-6 is produced by myocardium in heart disease and might be stimulated by ROS.…”

Inhibition of microRNA-25 by tumor necrosis factor α is critical in the modulation of vascular smooth muscle cell proliferation

“…A previous study indicated that tumor necrosis factor-α (TNF-α) is a major risk factor in atherosclerosis and coronary heart disease (8). TNF-α is a pleiotropic inflammatory cytokine that has been reported to serve a pathophysiological role in vascular atherosclerosis (9,10). In addition, TNF-α has been demonstrated to regulate the proliferation, apoptosis, migration and differentiation of VSMCs, which are critical in the pathogenesis of cardiovascular disease (8,11,12).…”